Search results for " Liv"

showing 10 items of 2456 documents

2017

Background and aims Nonalcoholic fatty liver disease is epidemiologically associated with hepatic and metabolic disorders. The aim of this study was to examine whether hepatic fat accumulation has a causal role in determining liver damage and insulin resistance. Methods We performed a Mendelian randomization analysis using risk alleles in PNPLA3, TM6SF2, GCKR and MBOAT7, and a polygenic risk score for hepatic fat, as instruments. We evaluated complementary cohorts of at-risk individuals and individuals from the general population: 1515 from the liver biopsy cohort (LBC), 3329 from the Swedish Obese Subjects Study (SOS) and 4570 from the population-based Dallas Heart Study (DHS). Results Hep…

0301 basic medicinemedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industryFatty livermedicine.diseaseChronic liver disease3. Good health03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicineEndocrinologyInsulin resistanceLiver biopsyInternal medicineNonalcoholic fatty liver diseaseInternal MedicineMedicine030211 gastroenterology & hepatologySteatosisbusinessJournal of Internal Medicine
researchProduct

Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

2017

Background Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. Methods A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characteri…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMetaboliteMedicine (miscellaneous)lcsh:TX341-641Clinical nutritionBiology03 medical and health scienceschemistry.chemical_compoundFetge--MalaltiesInternal medicineLipid biosynthesisHepatic lipotoxicitymedicineMetabolomicsProspective cohort studylcsh:RC620-627Nutrition and DieteticsFatty acid metabolismResearchFatty livernutritional and metabolic diseasesmedicine.diseasedigestive system diseaseslcsh:Nutritional diseases. Deficiency diseases030104 developmental biologyEndocrinologychemistryLipotoxicityFatty acid metabolismSteatosislcsh:Nutrition. Foods and food supplyNon-alcoholic fatty liver diseaseNutrition & Metabolism
researchProduct

Protection in a model of liver injury is parallel to energy mobilization capacity under distinct nutritional status

2019

International audience; Objective: Dietary and energetic restrictions are endowed with protection against experimental injuries. However, a drop in cell energetic status under a critical threshold may prevent protection, as previously observed for livers isolated from rat donors undergoing 18-h fasting versus feeding. The aim of this study was to further explore, in the latter model, links between nutritional status, energy availability, and protection through lengthening of rat fasting to 24 h and withdrawal of energy sources from perfusions.Methods: Energy-free perfused ex vivo livers from fed, 18-h-fasted, and 24-h-fasted rats were studied during 135 min for cytolysis (potassium, asparta…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Nutritional Status030209 endocrinology & metabolismCaspase 303 medical and health scienceschemistry.chemical_compound0302 clinical medicineLactate dehydrogenaseInternal medicineAutophagymedicineAnimalsOrgan protection2. Zero hungerLiver injury030109 nutrition & dieteticsNutrition and DieteticsLiver injury modelGlycogenLiver cytolysisAutophagyEnergy mobilizationFastingSciences bio-médicales et agricolesProtective Factorsmedicine.diseaseLC3IIRats[SDV] Life Sciences [q-bio]PerfusionCytolysisDisease Models AnimalEndocrinologychemistryLiverApoptosisChemical and Drug Induced Liver InjuryEnergy sourceEnergy Metabolism
researchProduct

Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

2021

BACKGROUND AND AIMS: Electronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in nonalcoholic fatty liver disease (NAFLD), where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Disease (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues.APPROACH AND RESULTS: Researchers with an interest in EHR-based NAFLD research were invited to collect…

0301 basic medicinemedicine.medical_specialtyFIBROSIS STAGEBiomedical ResearchConsensusClinical SciencesImmunologyDiseaseMedical Biochemistry and MetabolomicsDIAGNOSISVALIDATIONArticle03 medical and health sciences0302 clinical medicineClinical ResearchNon-alcoholic Fatty Liver DiseaseEpidemiologyHealth caremedicineElectronic Health RecordsHumansGeneralizability theoryALGORITHMFATTY LIVER-DISEASEStatement (computer science)Gastroenterology & HepatologyHepatologybusiness.industryMORTALITYComparabilityClinical CodingReference Standards3. Good healthGood Health and Well Being030104 developmental biology3121 General medicine internal medicine and other clinical medicineFamily medicineInclusion and exclusion criteria030211 gastroenterology & hepatologyPatient SafetybusinessPsychologyREAL-WORLDCoding (social sciences)Hepatology
researchProduct

Chronic aspartame intake causes changes in the trans-sulphuration pathway, glutathione depletion and liver damage in mice

2017

No-caloric sweeteners, such as aspartame, are widely used in various food and beverages to prevent the increasing rates of obesity and diabetes mellitus, acting as tools in helping control caloric intake. Aspartame is metabolized to phenylalanine, aspartic acid, and methanol. Our aim was to study the effect of chronic administration of aspartame on glutathione redox status and on the trans-sulphuration pathway in mouse liver. Mice were divided into three groups: control; treated daily with aspartame for 90 days; and treated with aspartame plus N-acetylcysteine (NAC). Chronic administration of aspartame increased plasma alanine aminotransferase (ALT) and aspartate aminotransferase activities…

0301 basic medicinemedicine.medical_specialtyGlutamate-Cysteine LigaseClinical BiochemistryPhenylalanineBiochemistryMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAspartic acidmedicineAnimalsHumansCysteineAspartamelcsh:QH301-705.5lcsh:R5-920S-adenosylmethionineMethioninebiologyAspartameChemistryOrganic ChemistryCystathionine gamma-LyaseMethionine AdenosyltransferaseGlutathioneGlutathioneCystathionine beta synthaseN-acetylcysteineAcetylcysteine030104 developmental biologyEndocrinologyGCLCGene Expression RegulationLiverlcsh:Biology (General)BiochemistrySweetening Agents030220 oncology & carcinogenesisbiology.proteinChemical and Drug Induced Liver Injurylcsh:Medicine (General)Research PaperCysteineRedox Biology
researchProduct

Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imb…

2016

Gut microbiota is involved in obesity, metabolic syndrome and the progression of nonalcoholic fatty liver disease (NAFLD). It has been recently suggested that the flavonoid quercetin may have the ability to modulate the intestinal microbiota composition, suggesting a prebiotic capacity which highlights a great therapeutic potential in NAFLD. The present study aims to investigate benefits of experimental treatment with quercetin on gut microbial balance and related gut-liver axis activation in a nutritional animal model of NAFLD associated to obesity. C57BL/6J mice were challenged with high fat diet (HFD) supplemented or not with quercetin for 16 weeks. HFD induced obesity, metabolic syndrom…

0301 basic medicinemedicine.medical_specialtyGut floraDiet High-FatBiochemistryMice03 medical and health sciencesNon-alcoholic Fatty Liver DiseasePhysiology (medical)Internal medicineNonalcoholic fatty liver diseasemedicineAnimalsHumansObesityMetabolic SyndromebiologyFatty liverLipid metabolismLipid Metabolismmedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeIntestinesToll-Like Receptor 4Disease Models Animal030104 developmental biologyEndocrinologyLiverLipotoxicityImmunologyQuercetinInsulin ResistanceSteatosisMetabolic syndromeDysbiosisSignal TransductionFree Radical Biology and Medicine
researchProduct

The 9th Annual Conference of the International Liver Cancer Association (ILCA) 2015

2018

The 9th International Liver Cancer Association Annual Conference was held from 4th to 6th September 2015 in Paris, France, and attracted a record breaking 900 participants from 51 different countries and 386 submitted abstracts from scientists around the globe. The congress provided a comprehensive overview of current developments in primary liver cancers (i.e., hepatocellular carcinoma and cholangiocarcinoma) and covered a broad range of topics from basic science to clinical studies. Following the success of immunotherapies in recent years, a preconference workshop on immunopathogenesis and immunotherapy in hepatocellular carcinoma also took place. This report will provide a subjective su…

0301 basic medicinemedicine.medical_specialtyHepatologybusiness.industryeducationConference Reportmedicine.diseaseGastroenterology03 medical and health sciences030104 developmental biologyOncologyCholangiocellular carcinomaInternal medicineFamily medicinemedicineLiver cancerPrimary liver cancerbusinessHepatic Oncology
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice.

2015

Fatty liver accumulation results from an imbalance between lipid deposition and removal, driven by the hepatic synthesis of triglycerides and de novo lipogenesis. The habitual diet plays a relevant role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), and both risky (e.g., fructose) and protective foods (Mediterranean diet) have been described, but the contribution of excess calories remains pivotal. Accordingly, weight loss is the most effective way to promote liver fat removal. Several controlled studies have confirmed that an intense approach to lifestyle changes, carried on along the lines of cognitive-behavior treatment, is able to attain the desired 7%-10% weight loss,…

0301 basic medicinemedicine.medical_specialtyMediterranean diet03 medical and health sciences0302 clinical medicineFibrosisWeight lossNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseaseWeight LossmedicineHumansExerciseHepatologybusiness.industryFatty liverLipid metabolismHepatologymedicine.diseaseLipid MetabolismDiet030104 developmental biologyEndocrinologyLiverLipogenesis030211 gastroenterology & hepatologymedicine.symptomSedentary BehaviorbusinessHepatology (Baltimore, Md.)
researchProduct

Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease

2017

0301 basic medicinemedicine.medical_specialtyPathologyHepatologybusiness.industryLiver fibrosisGastroenterologyDiagnostic accuracymedicine.diseaseGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineInternal medicineNonalcoholic fatty liver diseaseMedicine030211 gastroenterology & hepatologyIn patientbusinessDigestive and Liver Disease
researchProduct